PMID- 36737060
OWN - NLM
STAT- MEDLINE
DCOM- 20230224
LR  - 20240218
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 22
IP  - 1
DP  - 2023 Jan
TI  - Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large 
      B-cell lymphoma.
PG  - 5-15
LID - 10.1080/14740338.2023.2177268 [doi]
AB  - INTRODUCTION: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a 
      highly effective therapy for patients with relapsed/refractory large B-cell 
      lymphoma (LBCL) and three CD19 CAR T-cell products (axicabtagene ciloleucel, 
      tisagenlecleucel and lisocabtagene maraleucel) are currently approved for this 
      indication. Despite the clinical benefit of CD19 directed CAR T-cell therapy, 
      this treatment is associated with significant morbidity from treatment-emergent 
      toxicities. AREAS COVERED: This Review discusses the safety considerations of 
      axicabtagene ciloleucel in patients with LBCL. This includes discussion of the 
      frequently observed immune-mediated toxicities of cytokine release syndrome and 
      immune effector cell-associated neurotoxicity syndrome. Additionally, we review 
      CAR T-cell therapy related cytopenias, infection, organ dysfunction and the more 
      recently described hemophagocytic lymphohistiocytosis. EXPERT OPINION: A thorough 
      understanding of the toxicities associated with CD19-directed CAR T-cell therapy 
      will facilitate the optimal selection of patients for this therapy. Furthermore, 
      knowledge of preventative measures of CAR T-cell related complications, and early 
      recognition and appropriate intervention will lead to the safe administration of 
      these therapies, and ultimately improved outcomes for our patients.
FAU - Nath, Karthik
AU  - Nath K
AUID- ORCID: 0000-0002-3881-5681
AD  - Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer 
      Center, New York, NY, USA.
FAU - Wudhikarn, Kitsada
AU  - Wudhikarn K
AUID- ORCID: 0000-0001-9528-8681
AD  - Division of Hematology and Center of Excellence in Translational Hematology, 
      Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
FAU - Alarcon Tomas, Ana
AU  - Alarcon Tomas A
AD  - Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio 
      Maranon, Madrid, Spain.
FAU - Perales, Miguel-Angel
AU  - Perales MA
AD  - Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan 
      Kettering Cancer Center, New York, NY, USA.
AD  - Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20230217
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - U2I8T43Y7R (axicabtagene ciloleucel)
RN  - 0 (cell-associated neurotoxicity)
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (Antigens, CD19)
SB  - IM
MH  - Humans
MH  - Immunotherapy, Adoptive/adverse effects
MH  - *Receptors, Chimeric Antigen
MH  - Treatment Outcome
MH  - *Lymphoma, Large B-Cell, Diffuse/pathology/therapy
MH  - Antigens, CD19/adverse effects
PMC - PMC9975047
MID - NIHMS1872022
OTO - NOTNLM
OT  - Axicabtagene ciloleucel
OT  - chimeric antigen receptor (CAR) T-cell therapy
OT  - cytokine release syndrome (CRS)
OT  - immune effector cell-associated neurotoxicity syndrome (ICANS)
OT  - large B-cell lymphoma (LBCL)
EDAT- 2023/02/04 06:00
MHDA- 2023/02/25 06:00
PMCR- 2024/02/17
CRDT- 2023/02/03 20:32
PHST- 2023/02/04 06:00 [pubmed]
PHST- 2023/02/25 06:00 [medline]
PHST- 2023/02/03 20:32 [entrez]
PHST- 2024/02/17 00:00 [pmc-release]
AID - 10.1080/14740338.2023.2177268 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2023 Jan;22(1):5-15. doi: 10.1080/14740338.2023.2177268. 
      Epub 2023 Feb 17.